Durant 1997.

Methods	Randomised, double‐blind, placebo‐controlled trial. Generation of allocation sequence: unclear. Double blind: not specified. Withdrawal/dropouts: not reported. Intention to treat analyses: yes.
Participants	Study country: France. Setting: hospitals. 43 asymptomatic HIV positive patients with CD4 cell counts between 25 and 50 millions per litre (22 in SPV30 (990 mg/day) group, and 21 in placebo group). Diagnostic criteria not described.
Interventions	Experiment: SPV30 (Buxus sempervirens L. preparations), two capsules (165 mg each) every eight hours daily (990 mg/d), for 30 weeks. Control: Placebo, two capsules every eight hours, for 30 weeks.
Outcomes	AIDS related complex; CD4 cell count , and adverse events.
Notes	Raw data were not available from the abstract.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear